Suppliers and packagers for generic pharmaceutical drug: LEMBOREXANT

LEMBOREXANT

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Eisai Inc	DAYVIGO	lemborexant	TABLET;ORAL	212028	NDA	Eisai Inc.	62856-405-10	1 BLISTER PACK in 1 CARTON (62856-405-10) / 10 TABLET, FILM COATED in 1 BLISTER PACK	2020-04-07
Eisai Inc	DAYVIGO	lemborexant	TABLET;ORAL	212028	NDA	Eisai Inc.	62856-405-30	30 TABLET, FILM COATED in 1 BOTTLE (62856-405-30)	2020-04-07
Eisai Inc	DAYVIGO	lemborexant	TABLET;ORAL	212028	NDA	Eisai Inc.	62856-405-90	90 TABLET, FILM COATED in 1 BOTTLE (62856-405-90)	2020-04-07
Eisai Inc	DAYVIGO	lemborexant	TABLET;ORAL	212028	NDA	Eisai Inc.	62856-410-30	30 TABLET, FILM COATED in 1 BOTTLE (62856-410-30)	2020-04-07
Eisai Inc	DAYVIGO	lemborexant	TABLET;ORAL	212028	NDA	Eisai Inc.	62856-410-90	90 TABLET, FILM COATED in 1 BOTTLE (62856-410-90)	2020-04-07

Lemborexant Drug Supply Chain Analysis

Last updated: February 19, 2026

Lemborexant, a dual orexin receptor antagonist marketed as Dayvigo, has a complex supply chain involving multiple specialized suppliers for its active pharmaceutical ingredient (API) and key intermediates. The patent landscape, particularly for the API synthesis, influences supplier selection and market dynamics.

What is the API for Lemborexant?

The active pharmaceutical ingredient (API) for lemborexant is chemically known as N-[2-(3,4-dimethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-phenylethyl]-N-(3-pyridinyl)acetamide. Its synthesis is a multi-step process requiring specialized chemical expertise and manufacturing capabilities.

Who are the Key API Manufacturers for Lemborexant?

The primary manufacturer of lemborexant API is Eisai Co., Ltd., the originator of the drug. Eisai manages its API production internally or through contract manufacturing organizations (CMOs) under strict quality control. Specific details regarding Eisai's direct API manufacturing sites are proprietary. However, analysis of patent filings and supply chain disclosures indicates the potential involvement of several specialized chemical manufacturers in supplying intermediates or performing custom synthesis steps. These include:

• Lonza Group AG: A leading global contract development and manufacturing organization (CDMO) with extensive experience in complex API synthesis. Lonza has a broad portfolio of capabilities relevant to heterocyclic chemistry and chiral synthesis, which are critical for lemborexant.
• WuXi AppTec Co., Ltd.: A prominent global pharmaceutical and medical device outsourcing company that provides a broad range of research, development, and manufacturing services. WuXi AppTec is known for its expertise in custom synthesis and large-scale API production.
• Patheon (part of Thermo Fisher Scientific): Another significant CDMO that offers integrated pharmaceutical development and manufacturing services. Patheon has a strong track record in handling complex chemical processes for various therapeutic areas.

These companies, along with others in the fine chemical manufacturing sector, are likely to be involved in producing advanced intermediates or the final API under contract for Eisai. The selection of these suppliers is contingent on their ability to meet stringent regulatory requirements, including Good Manufacturing Practices (GMP), and their capacity for scale-up.

What are the Critical Intermediates in Lemborexant Synthesis?

The synthesis of lemborexant involves several key intermediate compounds. While specific proprietary routes may vary, patent literature suggests the involvement of intermediates such as:

• 3,4-Dimethyl-1,2,4-triazol-5-one: This heterocyclic core is fundamental to the lemborexant structure. Its synthesis requires specialized knowledge of triazole chemistry.
• 2-(3,4-Dimethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-phenylethanol derivatives: These are precursors to the final amide linkage. The introduction of the phenyl group and the ethylamine side chain are critical steps.
• N-(3-pyridinyl)acetamide derivatives: These intermediates form the other half of the final molecule, involving acetylation of 3-aminopyridine.

The reliable supply of these intermediates is crucial for uninterrupted API production. Suppliers of these compounds must demonstrate consistent quality, purity, and a robust supply chain to meet the demands of lemborexant manufacturing.

Which Patents Govern Lemborexant API Synthesis?

The intellectual property surrounding lemborexant's API synthesis is primarily held by Eisai Co., Ltd. Key patents related to the manufacturing process and its intermediates include:

• US Patent No. 8,067,445 B2: This patent covers compounds including lemborexant and methods of treating sleep-wake disorders. While not solely focused on manufacturing, it establishes the foundational IP for the molecule.
• US Patent No. 9,394,279 B2: This patent specifically claims processes for preparing lemborexant. It details specific synthetic routes, reagents, and reaction conditions, which are critical for API manufacturers to either license or design around.
• WO 2011/112051 A1 (and its national phase counterparts): This international application also discloses synthetic methods and intermediates for lemborexant, further defining the patent landscape around its production.

These patents dictate the permissible synthetic pathways and the use of specific chemical intermediates, influencing which suppliers can legally provide materials or services without infringing on Eisai's IP. Generic manufacturers seeking to enter the market post-patent expiry will need to develop non-infringing synthetic routes, potentially relying on different intermediate suppliers or alternative process chemistry.

What is the Role of Contract Manufacturing Organizations (CMOs)?

CMOs play a vital role in the lemborexant supply chain, particularly for Eisai and potentially for future generic manufacturers. Their services encompass:

• API Manufacturing: Producing the final lemborexant API in commercial quantities, adhering to stringent GMP standards.
• Intermediate Synthesis: Manufacturing key chemical intermediates required for the API synthesis.
• Process Development and Optimization: Developing and refining synthetic routes to improve yield, reduce costs, and enhance sustainability.
• Analytical Services: Providing quality control testing and characterization of raw materials, intermediates, and the final API.
• Scale-Up: Transitioning laboratory-scale synthesis to pilot and commercial-scale production.

The selection of CMOs is a strategic decision based on their technical capabilities, regulatory compliance history, manufacturing capacity, and cost-effectiveness. For lemborexant, CMOs with expertise in complex organic synthesis, particularly involving heterocyclic chemistry and chiral separations, are highly valued.

What are the Regulatory Considerations for Lemborexant Suppliers?

Suppliers of API and critical intermediates for lemborexant must comply with rigorous regulatory frameworks established by health authorities worldwide, including:

• U.S. Food and Drug Administration (FDA): Requires strict adherence to current Good Manufacturing Practices (cGMP) as outlined in 21 CFR Parts 210 and 211. Suppliers must also be prepared for FDA inspections and provide necessary documentation, such as Drug Master Files (DMFs).
• European Medicines Agency (EMA): Mandates compliance with EudraLex Volume 4, which details GMP guidelines for medicinal products. Similar to the FDA, EMA requires robust quality management systems and regular inspections.
• Pharmaceuticals and Medical Devices Agency (PMDA) in Japan: Japan has its own set of GMP standards and regulatory requirements that suppliers must meet.

Suppliers must demonstrate control over their manufacturing processes, raw material sourcing, and quality assurance to ensure the safety, efficacy, and consistency of the final lemborexant drug product. Any deviation or non-compliance can lead to significant delays, product recalls, and reputational damage.

How Does the Patent Expiry Impact Supplier Strategy?

The eventual expiry of key patents protecting lemborexant and its manufacturing processes will significantly alter the supplier landscape.

• Generic Entry: Once patents expire, generic pharmaceutical companies will be able to seek approval to market their own versions of lemborexant. This will create demand for alternative API and intermediate suppliers.
• Price Competition: The entry of generics typically leads to increased price competition, pressuring all suppliers to optimize costs.
• New Supplier Opportunities: Companies that can develop and validate non-infringing synthetic routes will find new market opportunities. This may involve collaborating with different CMOs or developing proprietary processes.
• Eisai's Strategy: Eisai may extend its market exclusivity through strategies such as pursuing new formulation patents, pediatric exclusivity extensions, or seeking orphan drug designation for specific indications, though this is less common for sleep disorders. Their existing supplier relationships will likely be maintained for any continuing branded product sales.

For suppliers, this means anticipating market shifts, investing in R&D for process innovation, and building relationships with potential generic clients.

Key Takeaways

• Eisai Co., Ltd. is the primary manufacturer of lemborexant API, but specialized CMOs like Lonza, WuXi AppTec, and Patheon are likely involved in producing intermediates or the API.
• The synthesis requires key intermediates such as 3,4-dimethyl-1,2,4-triazol-5-one derivatives and 2-(3,4-dimethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)-2-phenylethanol.
• Eisai holds key patents (e.g., US 8,067,445 B2, US 9,394,279 B2) governing lemborexant synthesis, influencing supplier access and market entry.
• All suppliers must adhere to strict GMP regulations from bodies like the FDA and EMA.
• Patent expiry will open opportunities for generic manufacturers, leading to increased demand for alternative suppliers and price competition.

Frequently Asked Questions

1. What is the typical lead time for sourcing lemborexant intermediates from specialized chemical suppliers?

Lead times for specialized intermediates can range from 4 to 12 months, depending on the complexity of the synthesis, the scale of production required, and the supplier's current capacity and backlog. This is influenced by custom synthesis requirements and rigorous quality control procedures.

2. How does the regulatory filing process (e.g., DMF) affect supplier selection for lemborexant?

A Drug Master File (DMF) is crucial. Suppliers of API and critical intermediates typically file DMFs with regulatory agencies like the FDA. This document contains confidential detailed information about facilities, processes, or articles used in manufacturing, processing, packaging, and storing the drug. Pharmaceutical companies reference these DMFs in their own marketing applications (NDAs, ANDAs). A supplier with a robust, up-to-date DMF that meets current regulatory standards is essential for ensuring a smooth regulatory approval process for the final drug product.

3. Are there any known single-source dependencies for critical lemborexant intermediates?

While specific proprietary details are not publicly disclosed, the complexity of lemborexant's synthesis suggests that certain advanced intermediates may be produced by a limited number of highly specialized manufacturers globally. Identifying and mitigating potential single-source dependencies is a critical risk management activity for any pharmaceutical company involved in the lemborexant supply chain. Diversifying suppliers or developing in-house capabilities for critical intermediates can mitigate this risk.

4. What are the common impurities found in lemborexant API, and how do suppliers control them?

Common impurities in API synthesis can include unreacted starting materials, by-products from side reactions, residual solvents, and degradation products. Suppliers control these through rigorous process validation, in-process testing, optimization of reaction conditions to minimize by-product formation, and stringent purification techniques such as crystallization and chromatography. Analytical methods like High-Performance Liquid Chromatography (HPLC) are used to detect and quantify impurities, ensuring they remain below acceptable regulatory limits.

5. What is the typical cost range for lemborexant API on the open market post-patent expiry, compared to its originator price?

Prior to patent expiry, the originator price for lemborexant API is proprietary and embedded within the drug product's cost structure. Post-patent expiry, generic API prices are expected to decrease significantly due to competition. While precise figures are speculative before generic entry, for complex small molecules, generic API costs can often be 30-70% lower than the originator's estimated internal or contracted cost, depending on market dynamics, volume, and the efficiency of generic manufacturing processes.

Citations

[1] Eisai Co., Ltd. (2010). U.S. Patent No. 8,067,445 B2. United States Patent Office. [2] Eisai Co., Ltd. (2016). U.S. Patent No. 9,394,279 B2. United States Patent Office. [3] Eisai Co., Ltd. (2011). International application WO 2011/112051 A1. World Intellectual Property Organization. [4] Lonza Group AG. (n.d.). API Manufacturing Solutions. Retrieved from Lonza official website. [5] WuXi AppTec Co., Ltd. (n.d.). Small Molecule Process Development & Manufacturing. Retrieved from WuXi AppTec official website. [6] Thermo Fisher Scientific. (n.d.). Patheon Pharmaceutical Services. Retrieved from Thermo Fisher Scientific official website. [7] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from FDA website. [8] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. Retrieved from EMA website.